Details of Disease

General Information of Disease (ID: DISESSLZ)

Disease Name	Hepatitis D virus infection
Synonyms	Hepatitis delta virus hepatitis; Hepatitis D; HDV; Hepatitis delta virus caused hepatitis; hepatitis delta; delta hepatitis; Hepatitis D virus; hepatitis type D
Disease Class	1E50-1E51: Hepatitis virus infection
Definition	Inflammation of the liver in humans caused by hepatitis delta virus, a defective RNA virus that can only infect hepatitis B patients. For its viral coating, hepatitis delta virus requires the hepatitis B surface antigens produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
Disease Hierarchy	DISU6QAV: Post-viral disorder DISXXX35: Hepatitis DISVT5Q7: Viral hepatitis DISEM33Q: Infectious disease DISESSLZ: Hepatitis D virus infection
ICD Code	ICD-11 ICD-11: 1E51.2 ICD-10 ICD-10: B16-B18
Disease Identifiers	MONDO ID MONDO_0005789 MESH ID D003699 UMLS CUI C0011226 MedGen ID 4182 Orphanet ID 402823 SNOMED CT ID 707341005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bulevirtide	DMJUVE6	Approved	Peptide	[1]
Lonafarnib	DMGM2Z6	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Hepatitis delta antigen	DMMBNNK	Terminated	NA	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 4 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
IFNL3	TTRF4Q2	Limited	Genetic Variation	[4]
SLC10A1	TTWZRY5	Limited	Genetic Variation	[5]
DLL1	TT9CFQD	Strong	Biomarker	[6]
PSMB6	TT8EPLT	Strong	Biomarker	[6]
------------------------------------------------------------------------------------

This Disease Is Related to 6 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
UGT1A10	DEL5N6Y	Strong	Biomarker	[7]
UGT1A3	DEF2WXN	Strong	Biomarker	[7]
UGT1A4	DELOY3P	Strong	Biomarker	[7]
UGT1A5	DEPF954	Strong	Biomarker	[7]
UGT1A8	DE2GB8N	Strong	Biomarker	[7]
UGT1A9	DE85D2P	Strong	Biomarker	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DME(s)

This Disease Is Related to 6 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADAR	OTQNOHR8	Strong	Biomarker	[8]
CLTC	OTBFASMA	Strong	Biomarker	[9]
NRSN1	OT1KKXC8	Strong	Biomarker	[10]
PAEP	OTQA0NV4	Strong	Biomarker	[11]
PRSS3	OTN3S5YB	Strong	Biomarker	[12]
TMED2	OTBLO7RW	Strong	Biomarker	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DOT(s)

References

1	ClinicalTrials.gov (NCT03852719) Phase 3 Study of Bulevirtide in Patients With CHD. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002673)
4	Impact of interleukin 28B rs12979860 C/T polymorphism on severity of disease and response to treatment in hepatitis delta.J Infect Dev Ctries. 2017 Jan 30;11(1):58-64. doi: 10.3855/jidc.6872.
5	Characterisation of the hepatitis B virus cross-species transmission pattern via Na+/taurocholate co-transporting polypeptides from 11 New World and Old World primate species.PLoS One. 2018 Jun 18;13(6):e0199200. doi: 10.1371/journal.pone.0199200. eCollection 2018.
6	Parameters of human hepatitis delta virus genome replication: the quantity, quality, and intracellular distribution of viral proteins and RNA.J Virol. 2002 Apr;76(8):3709-19. doi: 10.1128/jvi.76.8.3709-3719.2002.
7	Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D.Lancet. 1994 Aug 27;344(8922):578-81. doi: 10.1016/s0140-6736(94)91966-6.
8	The large form of ADAR 1 is responsible for enhanced hepatitis delta virus RNA editing in interferon-alpha-stimulated host cells.J Viral Hepat. 2006 Mar;13(3):150-7. doi: 10.1111/j.1365-2893.2005.00663.x.
9	Tat-enhanced delivery of the C terminus of HDAg-L inhibits assembly and secretion of hepatitis D virus.Antiviral Res. 2018 Feb;150:69-78. doi: 10.1016/j.antiviral.2017.12.009. Epub 2017 Dec 14.
10	Hepatitis delta virus heterogeneity: a study by immunofluorescence.J Hepatol. 1991;13 Suppl 4:S125-9. doi: 10.1016/0168-8278(91)90043-b.
11	Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil.PLoS One. 2018 Sep 7;13(9):e0203831. doi: 10.1371/journal.pone.0203831. eCollection 2018.
12	Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study.J Viral Hepat. 1996 May;3(3):123-8. doi: 10.1111/j.1365-2893.1996.tb00002.x.